| [1] |
Bray F,Ferlay J,Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
| [2] |
Zhang H,Yang T,Wu M, et al. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management[J]. Cancer Lett, 2016, 379(2): 198-205.
|
| [3] |
Chinchilla-López P,Aguilar-Olivos NE,García-Gómez J, et al. Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma[J]. Ann Hepatol, 2017, 16(4): 565-568.
|
| [4] |
Liu Y,Li F,Gao F, et al. Periostin promotes tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling[J]. Oncotarget, 2016, 7(26): 40148-40159.
|
| [5] |
Boudria A,Abou Faycal C,Jia T, et al. VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta1 integrin/VEGFR autocrine loop[J]. Oncogene, 2018 Sep 7.
|
| [6] |
Ferrara N,Gerber HP,LeCouter J. The biology of VEGF and its receptors[J]. Nat Med, 2003, 9(6): 669-676.
|
| [7] |
Rahnemai-Azar AA,Weisbrod AB,Dillhoff M, et al. Intrahepatic cholangiocarcinoma: current management and emerging therapies [J]. Expert Rev Gastroenterol Hepatol, 2017, 11(5): 439-449.
|
| [8] |
王庆亮,许世磊,张鹏, 等. APF阳性肝内胆管细胞癌患者的临床特征及其预后因素[J/CD]. 中华肝脏外科手术学电子杂志, 2014, 3(6): 39-42.
|
| [9] |
Li S,Wang L,Meng Y, et al. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients[J]. Oncotarget, 2017, 8(25): 41282-41293.
|
| [10] |
Li YH,Hu CF,Shao Q, et al. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma[J]. J Transl Med, 2008, 6:1.
|
| [11] |
邓庆炎,陈宏,雒洪志, 等. 血管内皮生长因子C对胃癌淋巴结转移及微转移的预测价值研究[J/CD]. 中华普通外科学文献(电子版), 2018, 12(6): 405-408.
|
| [12] |
Dang YZ,Zhang Y,Li JP, et al. High VEGFR1/2 expression levels are predictors of poor survival in patients with cervical cancer[J]. Medicine (Baltimore), 2017, 96(1): e5772.
|
| [13] |
Hanahan D,Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646-674.
|
| [14] |
Chen ZB,Shen SQ,Ding YM, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus[J]. Med Oncol, 2009, 26(3): 365-371.
|
| [15] |
Lichtenberger BM,Tan PK,Niederleithner H, et al. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development[J]. Cell, 2010, 140(2): 268-279.
|
| [16] |
Hamerlik P,Lathia JD,Rasmussen R, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth[J]. J Exp Med, 2012, 209(3): 507-520.
|
| [17] |
Lin Y,Zhai E,Liao B, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer[J]. Oncotarget, 2017, 8(7): 11990-12002.
|
| [18] |
Peng S,Wang Y,Peng H, et al. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma[J]. Hepatology, 2014, 60(4): 1264-1277.
|
| [19] |
Luo M,Hou L,Li J, et al. VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin[J]. Cancer Lett, 2016, 373(1): 1-11.
|